Women on Ozempic-like drugs are 30% less likely to develop breast cancer: study

Nypost · Jun 02, 2026 · 624 words · By Rachel Sacks

Cancer Prevention Pharmaceutical Marketing Medical Innovation

headphones Listen to the eFinder podcast briefing

Ready to play

Daily briefing

What to know about Cancer Prevention

Women on Ozempic-like drugs are 30% less likely to develop breast cancer: study See more of our coverage in your search results.

Claims checked 9

Techniques found 2

Topics 3

Coverage spectrum

Coverage gap: Low Left coverage

Left0%

Center80%

Right20%

5 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Women on Ozempic-like drugs are 30% less likely to develop breast cancer: study See more of our coverage in your search results.

Why it matters

Add The New York Post on GoogleGLP-1 drugs aren’t just reducing weight — they may also be reducing the chances of developing one of the most common and deadliest cancers for women.

Common ground

Blockbuster weight loss drugs like Ozempic and Wegovy have been linked to numerous benefits beyond weight loss, such as cutting the risk of obesity-related cancers in half.

Perspective signals

The tension in the story is sharpened by Loaded Language, Glittering Generalities: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

Follow-up questions

What new context would change how readers understand this Cancer Prevention story?
What evidence would most clearly confirm or weaken the claim that An analysis of more than 110,000 women between the ages of 45 and 80 — the average age range of breast cancer diagnosis — found that those who took a GLP-1 were 30% less likely to develop the illness?
How does this story connect Cancer Prevention with Pharmaceutical Marketing over the next few days?

open_in_new Read the original article: https://nypost.com/2026/06/02/health/women-on-ozempic-like-drugs-30-less-likely-…

psychologyPropaganda Techniques Detected

eFinder identified 2 propaganda techniques in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning

Loaded Language 80% confidence

Using words with strong emotional connotations to influence an audience.

Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.

Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

warning

Glittering Generalities 70% confidence

Using vague, emotionally appealing phrases ('freedom', 'justice') without specifics.

Why it matters: Recognizing glittering generalities helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 9 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 6

info Single Source 1

help Insufficient Evidence 1

verified Verified 1

check_circle

Claim 1: “An analysis of more than 110,000 women between the ages of 45 and 80 — the average age range of breast cancer diagnosis — found that those who took a GLP-1 were 30% less likely to develop the illness.”

CORROBORATED

Three independent web search results confirm the specific details of the analysis: over 110,000 women, age range 45-80, and a 30% (or 30-35%) reduced likelihood of developing breast cancer.

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 agonists, GLP-1RAs, and informally as simply GLP-1s, are a class of medications that activate the GLP-1 receptor, causing reduced…
https://en.wikipedia.org/wiki/GLP-1_receptor_agonist

menu_book

wikipedia NEUTRAL — Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by int…
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1

menu_book

wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss. Tirzepatide is adminis…
https://en.wikipedia.org/wiki/Tirzepatide

+ 3 more evidence sources

info

Claim 2: “Previous research has also found that GLP-1 drugs were 41% more effective at preventing obesity-related cancers than bariatric surgery.”

SINGLE SOURCE

The provided evidence for this claim consists of general definitions of 'research' and links to ResearchGate, but contains no specific data or studies comparing GLP-1 drugs to bariatric surgery regarding cancer prevention effectiveness.

travel_explore

web search NEUTRAL — Research is creative and systematic work undertaken to increase the stock of knowledge. [1] It involves the collection, organization, and analysis of evidence to increase understanding of a topic, cha…
https://en.wikipedia.org/wiki/Research

travel_explore

web search NEUTRAL — Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.
https://www.researchgate.net/

travel_explore

web search NEUTRAL — Jul 25, 2023 · Research is a systematic and methodical process of inquiry aimed at exploring, analyzing, and interpreting information to answer specific questions or solve problems. Learn more about t…
https://ideascale.com/blog/what-is-research/

help

Claim 3: “This was seen in a study examining the effects of tirzepatide (sold as Mounjaro for diabetes and Zepbound for obesity) in mice, which resulted in about 20% body weight loss and reduced breast cancer tumor size.”

INSUFFICIENT EVIDENCE

No evidence was found in the provided search results to support or contradict the claim regarding tirzepatide studies in mice.

check_circle

Claim 4: “Women on Ozempic-like drugs are 30% less likely to develop breast cancer: study”

CORROBORATED

Multiple independent web search results from June 2026 confirm a retrospective analysis showing women on GLP-1 medications were approximately 30% less likely to develop breast cancer.

menu_book

wikipedia NEUTRAL — The glucagon-like peptide-1 receptor (GLP1R) is a G protein-coupled receptor (GPCR) found on beta cells of the pancreas and on neurons of the brain. It is involved in the control of blood sugar level …
https://en.wikipedia.org/wiki/Glucagon-like_peptide-1_recept…

+ 3 more evidence sources

check_circle

Claim 5: “Blockbuster weight loss drugs like Ozempic and Wegovy have been linked to numerous benefits beyond weight loss, such as cutting the risk of obesity-related cancers in half.”

CORROBORATED

Multiple sources indicate GLP-1 drugs like Ozempic and Wegovy are linked to significant reductions in obesity-related cancers, with one source specifically mentioning a risk reduction of 50% or more for four types of cancer.

menu_book

wikipedia NEUTRAL — Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for weight management. It can be administered by subcutaneous injection or tak…
https://en.wikipedia.org/wiki/Semaglutide

+ 3 more evidence sources

verified

Claim 6: “obesity is linked to 13 types of cancer, including breast, prostate, uterus, pancreas, colon, kidney and liver.”

VERIFIED

The CDC explicitly states that being overweight or obese is associated with a higher risk of 13 types of cancer. Other sources list the specific cancers mentioned (breast, colorectal, kidney, etc.), corroborating the list provided in the claim.

travel_explore

web search NEUTRAL — Jun 11, 2025 · Being overweight or having obesity are associated with a higher risk of getting 13 types of cancer. These cancers make up 40% of all cancers ...Missing: prostate, | Show results with:pr…
https://www.cdc.gov/cancer/risk-factors/obesity.html

travel_explore

web search NEUTRAL — Obesity has been linked to several common cancers including breast, colorectal, esophageal, kidney, gallbladder, uterine, pancreatic, and liver cancer.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9857053/

travel_explore

web search NEUTRAL — Jan 28, 2025 · Some of these studies have found lower risks of breast, endometrial, colon, and prostate cancers among people with obesity who had lost weight.Missing: uterus, | Show results with:uteru…
https://www.cancer.gov/about-cancer/causes-prevention/risk/o…

check_circle

Claim 7: “A study published last year found that people on GLP-1 drugs reduced their risk of 10 of the 13 obesity-associated cancers.”

CORROBORATED

A specific report from January 14, 2025, states that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers, and other PubMed/clinical data sources support the general reduction of risk for these cancers.

travel_explore

web search NEUTRAL — Oct 1, 2025 · This retrospective cohort study found that taking GLP-1RAs was associated with a reduced overall risk of cancer, including lower risks of ...
https://pubmed.ncbi.nlm.nih.gov/40839273/

travel_explore

web search NEUTRAL — Jan 14, 2025 · Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
https://www.medscape.com/viewarticle/new-weight-loss-drugs-m…

travel_explore

web search NEUTRAL — This study provides clinical data suggesting that GLP-1RAs may reduce the risk of specific OACs compared with insulins.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle…

check_circle

Claim 8: “Accounting for about 30% of all new female cancers annually, breast cancer is expected to affect more than 320,000 people this year.”

CORROBORATED

Two independent sources confirm that breast cancer accounts for about 30% of all new female cancers annually. One source specifically mentions the projection of over 320,000 people this year, while another provides a slightly higher figure (382,640), both supporting the 'more than 320,000' claim.

menu_book

wikipedia NEUTRAL — The breasts are two prominences located on the upper ventral region of the torso in humans and other primates. Both sexes develop breasts from the same embryological tissues. The relative size and dev…
https://en.wikipedia.org/wiki/Breast

menu_book

wikipedia NEUTRAL — Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer may include: a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from …
https://en.wikipedia.org/wiki/Breast_cancer

menu_book

wikipedia NEUTRAL — As a paraphilia, breast fetishism (also known as mastophilia, breast partialism, or mazophilia) is a sexual interest that focuses exclusively on the female breasts, and is a type of partialism. The te…
https://en.wikipedia.org/wiki/Breast_fetishism

+ 3 more evidence sources

check_circle

Claim 9: “a study from the University of Pennsylvania’s Perelman School of Medicine found more evidence that weight loss drugs could be cancer prevention tools.”

CORROBORATED

Multiple reports explicitly link the findings regarding GLP-1 drugs as cancer prevention tools to a study from Penn Medicine (University of Pennsylvania's Perelman School of Medicine).

menu_book

wikipedia NEUTRAL — Ronald Owen Perelman (; born January 1, 1943) is an American banker, businessman, investor, and philanthropist. MacAndrews & Forbes Incorporated, his company, has invested in companies with interests …
https://en.wikipedia.org/wiki/Ronald_Perelman

menu_book

wikipedia NEUTRAL — The Perelman School of Medicine, previously the University of Pennsylvania School of Medicine (Penn Med), is the medical school of the University of Pennsylvania, a private Ivy league research univers…
https://en.wikipedia.org/wiki/Perelman_School_of_Medicine

menu_book

wikipedia NEUTRAL — Raymond G. Perelman (August 22, 1917 – January 14, 2019) was an American businessman, investor, and philanthropist who served as the founder, chairman and CEO of RGP Holdings. He was the father of Ron…
https://en.wikipedia.org/wiki/Raymond_G._Perelman

+ 3 more evidence sources

info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.